Gracell Biotechnologies Inc.

GRCLNASDAQHealthcare

$10.25

+$0.01(+0.05%)

Market Cap$197973420

P/E Ratio—

52W High$10.435

52W Low$1.4

Avg Volume1.6M

Open$10.26

Beta-0.34

Forecast Market Cap PE Ratio

Gracell Biotechnologies Inc.（GRCL）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

grcl · 股价预测 · 8 位分析师（近3月）· FMP · 更新于 2024年3月26日

分析师评级与共识

基于过去 3 个月内 8 位华尔街分析师

Hold

8 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 8 · 买入占比: 37.5%

12 个月目标价

High

$6.00

Consensus

$6.00

-41.5% upside

Low

$6.00

Median: $6 · Last Close: $10.25

Gracell Biotechnologies Inc.（GRCL）的分析师共识为 Hold，基于过去 3 个月内 8 位华尔街分析师的评级。GRCL 的 12 个月平均目标价为 $6.00，相对当前价 $10.25 代表 -41.5% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-10	$10.25	↓ 0.05%	$10.24	$10.26

1-day model range: $10.24–$10.26. Peak: $10.26 (-0.05%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

43%50%7%

6Buy

7Neutral

1Sell

RSI (14)51.5Neutral

MACDBULLISH

Refreshes daily from EOD close

Moving Averages · GRCL · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$10.21BUY

MA 10$10.25SELL

MA 20$10.22BUY

MA 50$0.00NEUTRAL

MA 100$0.00NEUTRAL

MA 200$0.00NEUTRAL

Current $GRCL · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$10.24BUY

EMA 10$10.23BUY

EMA 20$10.20BUY

EMA 50$0.00NEUTRAL

EMA 100$0.00NEUTRAL

EMA 200$0.00NEUTRAL

Current $GRCL · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2024-02-22	Stifel	Downgrade ↓	Buy→Hold
2023-12-27	Wells Fargo	Downgrade ↓	Overweight→Equal Weight
2023-12-27	Piper Sandler	Downgrade ↓	Overweight→Neutral
2023-12-26	BTIG	Downgrade ↓	Buy→Neutral
2023-12-26	HC Wainwright & Co.	Downgrade ↓	Buy→Neutral
2023-09-05	Cantor Fitzgerald	Maintains	Overweight→Overweight
2023-09-04	Cantor Fitzgerald	Maintains	Overweight→Overweight
2023-08-30	Cantor Fitzgerald	Maintains	Overweight→Overweight
2023-08-29	Cantor Fitzgerald	Maintains	Overweight→Overweight
2023-08-29	Citigroup	Maintains	Buy→Buy

Stifel2024-02-22

Downgrade ↓

Buy→Hold

Wells Fargo2023-12-27

Downgrade ↓

Overweight→Equal Weight

Piper Sandler2023-12-27

Downgrade ↓

Overweight→Neutral

BTIG2023-12-26

Downgrade ↓

Buy→Neutral

HC Wainwright & Co.2023-12-26

Downgrade ↓

Buy→Neutral

Cantor Fitzgerald2023-09-05

Maintains

Overweight→Overweight

Cantor Fitzgerald2023-09-04

Maintains

Overweight→Overweight

Cantor Fitzgerald2023-08-30

Maintains

Overweight→Overweight

Cantor Fitzgerald2023-08-29

Maintains

Overweight→Overweight

Citigroup2023-08-29

Maintains

Buy→Buy

Wall Street analysts have recently issued updated ratings on Gracell Biotechnologies Inc. (GRCL) stock. Of the recent 27 rating actions, 0 were upgrades and 5 were downgrades. 8 analysts currently cover GRCL.

分析师推荐趋势

Buy ratings2 → 0↓ 2

Hold ratings0 → 1↑ +1

Sell ratings0 → 0

GRCL analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$0M

Revenue Next Year

$0M

↓ 65.8% YoY

EPS This Year

$-0.10

EPS Next Year

$-0.68

↑ 580.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast GRCL EPS of $-0.10 for the current fiscal year, based on estimates from 0 analysts. The GRCL revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

GRCL 股价预测由两类独立数据源支撑：来自 8 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。GRCL 的共识目标价为 $6.00（-41.5% 上行空间），分析师共识为 Hold。

GRCL 的短期预测（明日）为 $10.25（-0.05%）。

Gracell Biotechnologies Inc. 在 NASDAQ 上市，代码 GRCL。GRCL 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 38% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

GRCL 预测 · 8 个问题

根据 8 位华尔街分析师，GRCL 的 12 个月平均目标价为 $6.00，最高 $6.00、最低 $6.00。若有图表，中位目标价可在上方查看。相对当前价 $10.25，隐含约 -41.5% 的上行空间。

GRCL 目标价GRCL 分析师目标价GRCL 12个月目标价目标价 GRCL

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.